Personalised drugs delivered by personalised application devices are the new disruption in the health business
After energy and artificial intelligence, Disrupted Health is one of the main sectors set for disruption with a significant pace of change – but it’s also the one sector where disruptive technology will be effectively strangled by legacy legislation.
As previously reported nanobots will lead to ‘robotic pills’ – with the ability to deliver drugs directly to a diseased or broken cell – Google has recently been investing in such technology to help cure cancer – now a collaboration between health giant Novartis and startup Rani Therapeutics will provide for the delivery of ‘biological drugs‘ directly to the broken cell.
Here’s the article from TNW: “You could soon be taking a robot pill that delivers drugs with sugar needles (by Mic Wright)
The capsule is taken like a conventional pill, but contains tiny needles made of sugar that deliver drugs into the wall of the intestine.
The approach could make the dream of delivering large-molecule biologic drugs in pill form possible. Most previous attempts have been stymied as the compounds are broken down in the stomach.
The startup says it will be running feasibility studies over the next 18 to 24 months, evaluating which Novartis medicines can be delivered directly into the bloodstream using the device.
Rani’s previous backers include Google Ventures. It will now add Novartis to that roster. The pharmaceutical giant is taking part in a new fundraising round, with the possibility that it may forge a larger collaboration or license the technology.
Last year, Novartis teamed up with Google to begin the development of smart contact lenses designed to help diabetics track their blood glucose levels.”